Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive ...

KenvueKVUE stock yo-yoed Monday after the down-and-out health care player — known for brands like Aveeno, Band-Aid and ...

“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

The Company believes these measures help improve investors’ ability to understand the Company’s operating performance ... (conversion of stock-based awards, stock-based awards granted to individuals ...

Kenvue (NYSE:KVUE) recently experienced a 2% price increase over the past week, a move that coincides with notable executive changes. The replacement of the CEO with Kirk L. Perry as interim CEO, ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Alongside the leadership change, Kenvue revealed that its Board had previously initiated a comprehensive review of strategic alternatives and established a Strategic Review Committee. The review will ...